Indacaterol

Indacaterol maleate is a selective beta2-adrenergic agonist. Its chemical name is (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl]-8- hydroxy-1H-quinolin-2-one maleate.it is indicated for long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to hydroxyquinolones. It belongs to Beta-2 adrenergic agonist pharmacological group on the basis of mechanism of action. The Molecular Weight of Indacaterol is 508.56.
Contraindications
Indacaterol
Effects
The symptomatic adverse reactions produced by Indacaterol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Cough, Nasopharyngitis, oropharyngeal pain.
Indications
Indacaterol is primarily indicated in conditions like Chronic bronchitis, Chronic obstructive pulmonary disease, Emphysema.
Interactions
No data regarding the interactions of Indacaterol was found.
Interfrence
Risks
Drug should not be given to Paediatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
( indacaterol inhalation powder) Capsule Store Between 15°C-30°C. Protect from Sunlight and Moisture.
Warnings
Do not initiate in acutely deteriorating COPD patients. Do not use for relief of acute symptoms. Concomitant short-acting beta2- agonists can be used as needed for acute relief. Do not exceed the recommended dose. Excessive use or use inconjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal. Immediate hypersensitivity reactions may occur. Discontinue immediately. Life-threatening paradoxical bronchospasm can occur. Discontinue immediately. Use with caution in patients with cardiovascular or convulsive disorders, thyrotoxicosis or sensitivity to sympathomimetic drugs.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.